Market Place
Sourcing Support
Apollomics Presents Vebreltinib Data At ESMO Congress 2024
16 Sep 2024 //
GLOBENEWSWIRE
Apollomics Reports Positive Data For Vebreltinib In Solid Tumors
13 Aug 2024 //
GLOBENEWSWIRE
Apollomics: Vebreltinib Data At ASCO 2024
04 Jun 2024 //
GLOBENEWSWIRE
Avistone: Vebreltinib Approved in China for Rare Brain Glioma
25 Apr 2024 //
BUSINESSWIRE
Apollomics` Vebreltinib Approved in China for MET+ Gliomas
25 Apr 2024 //
GLOBENEWSWIRE
Apollomics Presents Vebreltinib Data at AACR Annual Meeting
10 Apr 2024 //
GLOBENEWSWIRE
Apollomics Announces Presentations of Vebreltinib Data at the 2024 AACR Meeting
02 Apr 2024 //
GLOBENEWSWIRE
Apollomics Presents Interim Data from Two Phase 2 Trials with Vebreltinib
04 Dec 2023 //
GLOBENEWSWIRE
Avistone Announces the First Approval of Vebreltinib for MET
17 Nov 2023 //
BUSINESSWIRE
Apollomics Announces the First Approval of Vebreltinib for MET
16 Nov 2023 //
GLOBENEWSWIRE
Apollomics Announces New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib
31 Oct 2023 //
GLOBENEWSWIRE
Avistone Announces Phase II Results for Vebreltinib at ESMO Congress
23 Oct 2023 //
BUSINESSWIRE
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients
23 Oct 2023 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.